Insulin, in normal physiological conditions, suppresses lipolysis, but, in insulin-resistant states, this suppression might not work efficiently, leading to elevated and dysfunctional fat breakdown and the release of FFAs into the circulation, which, in addition to reduced ATGL activity, contributes to metabolic disorders and may favor ATM. The gene discussed is PNPLA2; the disease is metabolic disease.